Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VERA
Upturn stock ratingUpturn stock rating

Vera Therapeutics Inc (VERA)

Upturn stock ratingUpturn stock rating
$21.27
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VERA (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

14 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $63.36

1 Year Target Price $63.36

Analysts Price Target For last 52 week
$63.36 Target price
52w Low $18.53
Current$21.27
52w High $51.61

Analysis of Past Performance

Type Stock
Historic Profit 371.66%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.34B USD
Price to earnings Ratio -
1Y Target Price 63.36
Price to earnings Ratio -
1Y Target Price 63.36
Volume (30-day avg) 14
Beta 1.19
52 Weeks Range 18.53 - 51.61
Updated Date 08/3/2025
52 Weeks Range 18.53 - 51.61
Updated Date 08/3/2025
Dividends yield (FY) -
Basic EPS (TTM) -3

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.8214
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -23.46%
Return on Equity (TTM) -39.49%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 800699610
Price to Sales(TTM) -
Enterprise Value 800699610
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.6
Shares Outstanding 63774200
Shares Floating 46894414
Shares Outstanding 63774200
Shares Floating 46894414
Percent Insiders 3.97
Percent Institutions 111.53

ai summary icon Upturn AI SWOT

Vera Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Vera Therapeutics, Inc. is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. It was founded in 2016 and went public in 2021. The company's initial focus was on oncology before pivoting to immunology.

business area logo Core Business Areas

  • Atacicept Development: Vera's primary focus is the development of atacicept for IgA nephropathy (IgAN) and other B cell-mediated autoimmune diseases. Atacicept is a fusion protein designed to reduce levels of BAFF and APRIL, two cytokines that contribute to B-cell survival and antibody production.

leadership logo Leadership and Structure

The leadership team includes key executives with experience in drug development and commercialization. The company has a board of directors providing strategic oversight.

Top Products and Market Share

overview logo Key Offerings

  • Atacicept (VRX-311): Atacicept is Vera's lead drug candidate, currently in Phase 3 clinical development for IgA nephropathy (IgAN). Market share is not applicable as the drug is not yet approved. Competitors include Calliditas Therapeutics (TARPEYO) and Travere Therapeutics (FILSPARI).

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry, particularly in the autoimmune disease space, is competitive and rapidly evolving. The demand for novel therapies is high, but regulatory hurdles and clinical trial risks remain significant.

Positioning

Vera Therapeutics is positioned as a late-stage biotechnology company with a promising therapeutic candidate targeting a specific disease mechanism in IgAN. Competitive advantages lie in the drug's novel mechanism of action and the unmet medical need in IgAN.

Total Addressable Market (TAM)

The estimated global IgAN market is expected to reach billions of dollars. Vera is attempting to capture a significant portion of this TAM with its Atacicept therapy.

Upturn SWOT Analysis

Strengths

  • Late-stage clinical program (Phase 3)
  • Novel mechanism of action
  • Experienced management team
  • Strong financial backing

Weaknesses

  • Single product focus (Atacicept)
  • Clinical trial risk
  • Dependence on regulatory approval
  • Limited commercial infrastructure

Opportunities

  • Expansion into other B-cell mediated autoimmune diseases
  • Potential for partnership or acquisition
  • Positive clinical trial results
  • Favorable regulatory environment

Threats

  • Clinical trial failure
  • Regulatory delays or rejection
  • Competition from other therapies
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • KDNY
  • TRVC

Competitive Landscape

Vera faces competition from established players with approved therapies for IgAN. Vera's advantage lies in Atacicept's unique mechanism of action, potentially offering a different treatment option for patients. However, its lack of an approved product puts it at a disadvantage compared to companies with established market presence.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily reflected in the advancement of Atacicept through clinical trials.

Future Projections: Future growth is highly dependent on the success of Atacicept's Phase 3 trial and subsequent regulatory approval. Analyst estimates vary based on their assessment of the drug's potential.

Recent Initiatives: Recent initiatives include the commencement and continuation of the ORIGIN3 Phase 3 clinical trial for Atacicept in IgAN.

Summary

Vera Therapeutics is a clinical-stage biotech company focused on developing Atacicept for IgAN. Its strength lies in its Phase 3 program and novel mechanism of action. A key risk is the potential for clinical trial failure. Positive clinical data is critical for the company to realize its potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market data is dynamic and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vera Therapeutics Inc

Exchange NASDAQ
Headquaters Brisbane, CA, United States
IPO Launch date 2021-05-14
Founder, President, CEO & Director Dr. Marshall W. Fordyce M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 152
Full time employees 152

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.